Organ On Chips MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy Organ ModelBy ApplicationBy End UserBy Technology

Organ-on-chip systems are microfluidic devices that recreate the structure and function of a specific human tissue or organ on a small chip, used to observe how living cells respond to a drug, chemical or disease condition under controlled flow and mechanical conditions. Buyers are primarily pharmaceutical and biotechnology researchers evaluating drug candidates before animal or clinical testing, alongside contract research organizations, academic laboratories and, increasingly, cosmetics and chemical safety testing groups seeking an alternative to animal-based methods. The category spans standalone chip devices, the instruments that operate them, and the software used to capture and interpret the resulting data.

Growth of 23.57% a year carries the global organ on chips market from USD 105 million in 2025 to USD 718 million in 2034. The full series behind that rate covers USD 30 million in 2020, USD 81 million in 2024, USD 132 million in 2026 and USD 329 million in 2030, with 2025 as the base year.

Composition changes more than the total does. Software & Services, at 26.34%, outgrows Instruments & Devices at 20.91%, and its share moves from 18% to 22%. Consumables (Chips & Reagents) stays the largest line throughout, at USD 50.4 million in 2025 and USD 359 million in 2034. Share moves toward Consumables (Chips & Reagents) and Software & Services and away from Instruments & Devices, though no line shrinks in revenue terms.

The organ model split puts Liver-on-Chip first, at USD 31.5 million and 30% of revenue in 2025, rising to USD 193.86 million and 27% in 2034. Multi-Organ / Other Models grows faster at 26.36% against 22.38%, moving from 20% of revenue to 24% by 2034. It cuts the same total as the product type axis from a different commercial angle, so revenue does not add across the two.

The regional order runs from North America at 42% of 2025 revenue down to Middle East and Africa at 3%. North America is worth USD 44.1 million in 2025 and USD 272.84 million in 2034; Europe, second at 30%, moves from USD 31.5 million to USD 193.86 million. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, three product type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global organ on chips market moves from USD 30 million in 2020 to USD 105 million in 2025 and USD 718 million by 2034, the forecast period compounding at 23.57% a year.
• Consumables (Chips & Reagents) is the largest product type line at USD 50.4 million in 2025, a 48% share, reaching USD 359 million and 50% of revenue by 2034.
• At 26.34%, Software & Services grows faster than any other product type line, moving from USD 18.9 million and 18% of revenue in 2025 to USD 157.96 million and 22% in 2034.
• The bull case puts 2034 revenue at USD 811 million and the bear case at USD 617 million, either side of the USD 718 million base case, each with its own stated assumption in the full report.
• North America holds 42% of global revenue in 2025 at USD 44.1 million, the largest of the five regions tracked, and reaches USD 272.84 million by 2034.
• The United States accounts for 90% of North America in the base year, worth USD 39.69 million in 2025 and reaching USD 245.56 million by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global organ on chips market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 23.57% rate carrying the total.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

The product type mix tilts toward Software & Services. Software & Services grows at 26.34% across 2026-2034 against 20.91% for Instruments & Devices, the widest spread on the product type axis. Shares follow: 18% to 22% for Software & Services, 34% to 28% for Instruments & Devices. Revenue rises on both sides; USD 18.9 million to USD 157.96 million and USD 35.7 million to USD 201.04 million respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

The regional balance moves. Asia Pacific moves from 21% of revenue in 2025 to 27% in 2034, worth USD 22.05 million rising to USD 193.86 million; Latin America moves from 4% of revenue in 2025 to 5% in 2034, worth USD 4.2 million rising to USD 35.9 million. The remaining regions grow in absolute terms while giving up share: North America at 42% moving to 38%, Europe at 30% moving to 27%, Middle East and Africa at 3% moving to 3%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Fifteen years without a discontinuity. Fifteen years of revenue run USD 30 million in 2020, USD 81 million in 2024, USD 105 million in 2025, USD 132 million in 2026, USD 329 million in 2030 and USD 718 million in 2034. Against 28.48% through the historical period, the 23.57% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the product type and regional mixes matter more to a forecast than the headline rate does.

Software & Services adds the most incremental growth

Separate the 23.57% into its parts and three show up: an already-large base compounding, the product type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 617 million by 2034, against USD 718 million in the base case

Upside case: USD 811 million by 2034

Concentration on the product type axis

USD 44.1 million of 2025 revenue is generated in North America, 42% of the global organ on chips market and reaches USD 272.84 million by 2034. Among the five regions it ranks first by revenue in both years.

Its share moves to 38% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Consumables (Chips & Reagents) largest at 48% of 2025 revenue, Software & Services fastest at 26.34%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The largest single market in North America is the United States, at USD 39.69 million in 2025 and USD 245.56 million in 2034. At 90% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 44.1 million in 2025 and USD 272.84 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Consumables (Chips & Reagents) at 48% of 2025 revenue, easing to 50% by 2034, and the fastest is Software & Services at 26.34%, from 18% to 22%. Because the country carries 90% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product type for the United States is reported separately in the full report.

In the United States, organ-on-chip systems function mainly as preclinical research tools used ahead of clinical testing, so most fall outside the FDA's medical device approval pathway unless a supplier makes a direct diagnostic or therapeutic claim for the device itself. The Food and Drug Administration has instead focused on how data generated from these microphysiological systems can be qualified and accepted to support investigational new drug submissions, shifting scrutiny toward the drug development use of the platform. Suppliers marketing chips for laboratory use are expected to meet general laboratory equipment safety practices, and any system incorporating human-derived cells must also observe biosafety and tissue-handling requirements set by public health authorities. Labelling should accurately describe intended research use to avoid triggering device classification.

The suppliers tracked in this study (Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis) compete in the United States across the product type lines above. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

4.2% of global revenue is generated in Canada; USD 4.41 million in 2025, reaching USD 27.28 million in 2034, and 10% of North America.

Europe holds 30% of the global organ on chips market in 2025, worth USD 31.5 million and reaches USD 193.86 million by 2034. It is a leading region on this axis, second by revenue throughout the period.

By 2034 the share stands at 27%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Consumables (Chips & Reagents) largest at 48% of 2025 revenue, Software & Services fastest at 26.34%. Europe is reported axis by axis and country by country in the full study.

USD 11.97 million of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 73.67 million by 2034. It accounts for 38% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 31.5 million in 2025 and USD 193.86 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Germany follows the product type mix reported at global level: Consumables (Chips & Reagents) is the largest line at 48% of 2025 revenue, moving to 50% by 2034, while Software & Services grows fastest at 26.34% and takes its share from 18% to 22%. Because the country carries 38% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Germany carries its own product type breakdown in the full report.

In Germany, organ-on-chip platforms sold for pharmaceutical and academic research are treated as laboratory instruments rather than medical devices, since they are not intended for direct diagnosis or treatment of a patient, and so they sit outside the scope enforced by the Federal Institute for Drugs and Medical Devices. Where a system incorporates human tissue or cell lines, suppliers must instead satisfy the country's biological safety and genetic engineering rules covering handling of biological material in a laboratory setting, alongside general product safety and machinery conformity marking that applies to laboratory apparatus sold within the European Union. Should a manufacturer later position a chip for diagnostic use, it would move under the EU's in vitro diagnostic medical device framework, bringing conformity assessment and post market surveillance obligations into force.

Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis are the suppliers covered in Germany. Volume sits in Consumables (Chips & Reagents) at 48% of 2025 revenue; movement sits in Software & Services at 26.34% growth. Weighting toward Europe means competing for 30% of 2025 global revenue, a base of USD 31.5 million moving to USD 193.86 million across the forecast period.

Within Europe, Switzerland accounts for 32% of regional revenue and 9.6% of the global total, worth USD 10.08 million in 2025 and USD 62.04 million by 2034.

Within Europe, the United Kingdom accounts for 20% of regional revenue and 6% of the global total, worth USD 6.3 million in 2025 and USD 38.77 million by 2034.

Asia Pacific holds 21% of the global organ on chips market in 2025, worth USD 22.05 million and reaches USD 193.86 million by 2034. Among the five regions it ranks third by revenue in both years.

Its share rises to 27% over the forecast period, because it outgrows the market's 23.57%; the revenue added here is disproportionate to where the region started.

The product type mix reported at global level applies here, with Consumables (Chips & Reagents) the largest line at 48% of 2025 revenue and Software & Services the fastest-growing at 26.34%. The full report breaks Asia Pacific out along every axis and by country.

Japan is the largest market within Asia Pacific, generating USD 7.72 million in 2025 and projected to reach USD 67.85 million by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 22.05 million in 2025 and USD 193.86 million in 2034, it is the country the full report breaks out in detail.

The product type pattern in Japan is the global one: 48% of 2025 revenue in Consumables (Chips & Reagents), 50% by 2034, against 26.34% growth in Software & Services taking it from 18% to 22%. Because the country carries 35% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product type for Japan is reported separately in the full report.

In Japan, organ-on-chip systems intended for laboratory and drug discovery use are generally treated as research equipment outside the scope of the Pharmaceuticals and Medical Devices Act, since that law targets devices used for diagnosis or treatment of a patient and not tools applied earlier in the development pipeline. The Pharmaceuticals and Medical Devices Agency has shown willingness to accept data produced on qualified microphysiological systems as supporting evidence within a drug application, placing its oversight on scientific validation of the platform's results instead of on licensing the hardware itself. A chip incorporating living human or animal cells must still meet the country's biosafety and laboratory handling standards for biological material, and any claim of diagnostic function would require the supplier to pursue device approval under the same Act.

Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis are the suppliers covered in Japan. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. A supplier weighted toward Asia Pacific is competing over a base of USD 22.05 million in 2025 reaching USD 193.86 million by 2034, 21% of global revenue at the start of that period.

Within Asia Pacific, China accounts for 30% of regional revenue and 6.3% of the global total, worth USD 6.62 million in 2025 and USD 58.16 million by 2034.

Within Asia Pacific, South Korea accounts for 20% of regional revenue and 4.2% of the global total, worth USD 4.41 million in 2025 and USD 38.77 million by 2034.

4% of the global organ on chips market sits in Latin America in 2025, worth USD 4.2 million and reaches USD 35.9 million by 2034. Among the five regions it ranks fourth by revenue in both years.

5% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 23.57%; the revenue added here is disproportionate to where the region started.

Within the region the product type split tracks the global one; 48% of 2025 revenue in Consumables (Chips & Reagents), fastest growth of 26.34% in Software & Services. Per-axis and per-country detail for Latin America sits in the full report.

USD 2.52 million of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 21.54 million by 2034. 60% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 4.2 million and USD 35.9 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Consumables (Chips & Reagents) at 48% of 2025 revenue, easing to 50% by 2034, and the fastest is Software & Services at 26.34%, from 18% to 22%. Its 60% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by product type separately.

In Brazil, organ-on-chip devices marketed for research and drug screening purposes are generally treated as laboratory instruments and fall outside the medical device registration requirements enforced by the National Health Surveillance Agency, since that authority's remit centers on devices intended for direct diagnosis or treatment of a patient. A supplier working with human or animal derived cell lines must instead observe the biosafety approval process overseen by the National Technical Biosafety Commission, covering handling and containment of biological material used inside the chip. Should a manufacturer seek to market a chip with a diagnostic claim, the device would need to be classified and registered with the health surveillance agency before sale, bringing labelling and quality system obligations that do not otherwise apply to a research-only instrument.

Competition in Brazil runs between the suppliers this study tracks: Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis. The commercially relevant division is 48% of 2025 revenue in Consumables (Chips & Reagents), where the volume is, against 26.34% growth in Software & Services, where share moves. A supplier weighted toward Latin America is competing over a base of USD 4.2 million in 2025 reaching USD 35.9 million by 2034, 4% of global revenue at the start of that period.

Mexico is sized at USD 1.26 million in 2025, rising to USD 10.77 million by 2034; 1.2% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

3% of the global organ on chips market sits in Middle East and Africa in 2025, worth USD 3.15 million and reaches USD 21.54 million by 2034. Among the five regions it ranks fifth by revenue in both years.

3% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Within the region the product type split tracks the global one; 48% of 2025 revenue in Consumables (Chips & Reagents), fastest growth of 26.34% in Software & Services. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

The largest single market in Middle East and Africa is Israel, at USD 1.73 million in 2025 and USD 11.85 million in 2034. Its 55% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 3.15 million to USD 21.54 million over the same period, and this is the market carrying the country-level detail in the full report.

Israel buys along the same lines as the market globally; Consumables (Chips & Reagents) first at 48% of 2025 revenue and 50% in 2034, Software & Services fastest at 26.34% on a share moving from 18% to 22%. With 55% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product type revenue for Israel appears on its own in the full report.

In Israel, organ-on-chip platforms intended for laboratory and preclinical research use sit outside the medical device licensing process administered by the Ministry of Health's Medical Device division, because that process is reserved for devices intended for direct patient diagnosis or treatment. A laboratory working with human or animal cell material inside these systems must still meet the ministry's biosafety and laboratory practice requirements governing handling of biological material, and any system supplied for use in a certified laboratory is expected to conform to general laboratory equipment and electrical safety standards. Where a developer later seeks to market a chip with a diagnostic intended use, that device would then require full registration and classification under the country's medical device law before it could be sold or used clinically.

Competition in Israel runs between the suppliers this study tracks: Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. A supplier weighted toward Middle East and Africa is competing over a base of USD 3.15 million in 2025 reaching USD 21.54 million by 2034, 3% of global revenue at the start of that period.

0.75% of global revenue is generated in the United Arab Emirates; USD 0.79 million in 2025, reaching USD 5.39 million in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product Type, Organ Model, Application, End User, Technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.